Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News | November 11, 2011
November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non-...
News | November 11, 2011
November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial...
News | November 09, 2011
November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting...
News | November 08, 2011
November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which...
News | November 08, 2011
November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating...
News | November 07, 2011
November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter...
Technology | November 02, 2011
Nov. 2, 2011 –  The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus-...
News | November 01, 2011
November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research...
News | October 18, 2011
October 18, 2011 — Boston Scientific Corp. has begun a phased launch of its Promus Element everolimus-eluting platinum...
Feature | October 14, 2011 | Dave Fornell
October 14, 2011 – A U.S. Food and Drug Administration (FDA) review panel gave its unanimous recommendation for the...
Blog | October 11, 2011
The Holy Grail sought for more than two decades by interventional cardiology has been proof that minimally invasive,...
Feature | October 11, 2011 | Dave Fornell
The Holy Grail sought for more than two decades by interventional cardiology has been proof that minimally invasive,...
News | October 07, 2011
October 7, 2011 — Biosensors has announced completion of its acquisition of JW Medical Systems Ltd. (JWMS), one of the...
Feature | October 04, 2011
October 4, 2011 – Abbott today said it began enrolling U.S. patients in the EXCEL (Evaluation of Xience Prime or Xience...
Feature | September 26, 2011 | Dave Fornell
There have been several key news items from the U.S. stent market over the past year. These include the introduction of...